Abbott Laboratories (ABT) continues to be a hot topic of discussion in the investment world, leading in performance on strong trading days and outclassing competitors. Despite a number of losses, ABT's stock price rose 3.4%, and investors who put their money into Abbott Laboratories five years ago would have seen a 46% return. However, the company's shares fell following Q2 guidance which outweighed the earnings beat. Despite the seeming setback, several brokers and investors still consider ABT a good investment. The company boosts annual guidance, driven by strong medical devices sales. This bolsters the confidence of investors such as Envestnet Asset Management Inc., who purchased a massive 265,316 shares of ABT. But potential challenges are lurking around the corner; notably, a class action lawsuit against Abbott's Glucerna products persists. Additionally, there's been a notable insider sale from an Executive Vice President, which could signal hesitation. Regardless, most investors are suggested to retain Abbott as a profitable stock holding for now.
Abbott Laboratories ABT News Analytics from Mon, 30 Oct 2023 07:00:00 GMT to Sun, 09 Jun 2024 13:15:06 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor -2
